University of Rochester

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Rochester sits in the top decile of US sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count).

636 total trials 94 currently recruiting 448 completed early-phase tilt top decile by trial count

University of Rochester: 636 sponsored US clinical trials, 94 recruiting.

University of Rochester sponsors 636 registered US clinical trials on ClinicalTrials.gov, 94 of them currently recruiting, and 448 completed. 54 of these trials are in Phase 3-4 (later-stage) and 147 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 7 trials.

Top-decile sponsor footprint

University of Rochester ranks in the top decile of sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

448 of 506 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

636 total, page 12 of 13

COMPLETED Phase 1

PROS Brief Smoking Cessation Counseling in Pediatric Practice to Reduce Secondhand Smoke Exposure of Young Children

NCT00135213

TERMINATED Phase 1

Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.

NCT00288808

COMPLETED

A Study to Examine the Relationship Between Sleep Apnea and Cleft Lip/Palate

NCT00156442

COMPLETED Phase 2

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00309998

COMPLETED NA

Safety and Efficacy of Laparoscopic Truncal Vagotomy for the Treatment of Obesity

NCT00285220

COMPLETED

Emergency Pharmacist Safety Study

NCT00382434

COMPLETED Phase 2

Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)

NCT00212316

COMPLETED Phase 3

Study of Antidepressants in Parkinson's Disease

NCT00086190

COMPLETED NA

Treatment of Insomnia Secondary to Chronic Pain

NCT00127790

COMPLETED NA

Randomized Trial for Botox Urinary Incontinence

NCT00178191

TERMINATED NA

Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence

NCT00178282

COMPLETED Phase 2

Bortezomib in Treating Patients With Myelodysplastic Syndromes

NCT00262873

COMPLETED

Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

NCT00178152

COMPLETED Phase 2

Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT00262860

COMPLETED Phase 4

Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis

NCT00156520

COMPLETED Phase 1

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

NCT00258271

COMPLETED NA

Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions

NCT00178178

COMPLETED Phase 4

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

NCT00156533

COMPLETED Phase 4

The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia

NCT00124384

COMPLETED Phase 2

Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

NCT00178269

COMPLETED Phase 4

PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

NCT00178425

COMPLETED Phase 1

Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children

NCT00178490

COMPLETED Phase 2

Maintaining HIV Prevention Gains in Female Adolescents

NCT00161343

COMPLETED

A Qualitative Study About Smoking Practices

NCT00156481

TERMINATED

Radiation Dosimetry in Teeth

NCT00178347

COMPLETED

Sleep Architecture and Chemotherapy-Related Fatigue

NCT00178204

COMPLETED Phase 1

Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin

NCT01785615

COMPLETED

Pilot Study to Assess the Effectiveness of Tonsil and Adenoidectomy (T+A) in Overweight Children and Adolescents

NCT00222963

COMPLETED

Comparison of Educational Services and Outcomes for Patients Treated for Childhood Cancer

NCT00178386

COMPLETED NA

Workplace-Sponsored Program to Reduce Obesity

NCT00123513

COMPLETED Phase 4

Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence

NCT00178685

COMPLETED NA

Cognitive Behavioral Therapy for the Treatment of Depression-Related Insomnia

NCT00255905

COMPLETED Phase 1

Effects of Music Therapy on Huntington's Disease

NCT00178360

COMPLETED

Vitamin E and Male Infertility

NCT00178516

COMPLETED

Attitudes About Smoking: A Telephone Survey

NCT00156494

COMPLETED Phase 2

Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer

NCT00178373

COMPLETED Phase 1

Music Therapy for Patients Being Weaned From Mechanical Ventilation

NCT00178139

TERMINATED Phase 2

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

NCT00258297

COMPLETED Phase 2

Evaluation of a School-Based Training Program for Suicide Prevention

NCT00118443

COMPLETED Phase 2

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

NCT00262808

COMPLETED NA

Lexapro in the Treatment of Patients With Postpartum Depression

NCT00277108

COMPLETED Phase 2

NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

NCT00076492

COMPLETED

MMR and Varicella Vaccine in Premature Infants

NCT00156559

COMPLETED Phase 1

Diet and Behavior in Young Children With Autism

NCT00090428

COMPLETED NA

Interventions for Depressed Low Income Mothers and Their Infants

NCT00105573

TERMINATED NA

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

NCT00255684

COMPLETED NA

CT Scan Using IV Contrast Alone for Pediatric Appendicitis

NCT00716703

COMPLETED NA

Office-Based Asthma Screening Intervention

NCT00156468

COMPLETED NA

Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage

NCT05098236

COMPLETED Phase 2

Nesiritide and Vo2 Max in Heart Failure Patients

NCT00240084

← Previous Page 12 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 66
Phase 2 81
Phase 3 20
Phase 4 34

What is open in the University of Rochester pipeline

94 recruiting of 636 indexed (15% open); 448 completed (70%).

Phase mix: 54 late (III/IV) vs 147 early (I/II) (early-phase heavy).

Top condition: Cancer (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Rochester: open-pipeline peers nationwide

Peers matched on 636 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share University of RochesterUS Department of Veterans AffairsUniversity of Southern CaliforniaBaylor College of MedicineUniversity of California, DavisLoma Linda UniversityDompé Farmaceutici S.p.AVanderbilt-Ingram Cancer CenterBrown University
University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 636 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Rochester page

636 registered trials is a research-attention snapshot, not an endorsement of University of Rochester or any single study.

  • 94 of University of Rochester's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cancer is the condition University of Rochester studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Rochester pipeline card: 636 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.